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Glioblastoma multiforme (GBM), a greatly aggressive malignancy of the brain, is correlated with a poor
prognosis and low rate of survival. Up to now, chemotherapy and radiation therapy after surgical ap-
proaches have been the treatments increasing the survival rates. The low efficacy of mentioned therapies
as well as their side-effects has forced researchers to explore an appropriate alternative or comple-
mentary treatment for glioblastoma. In experimental models, it has been shown that curcumin has
therapeutic potentials to fight against GBM. Given that curcumin has pharmacological effects against
cancer stem cells, as major causes of resistance to therapy in glioblastoma cells. Moreover, it has been
showed that curcumin exerts its therapeutic effects on GBM cells via affecting on apoptosis, oxidant
system, and inflammatory pathways. Curcumin would possess a synergistic impact with chemothera-
peutic agents. Herein, we summarized the current findings on curcumin as therapeutic agent in the
treatment of GBM.
© 2020 Elsevier Masson SAS. All rights reserved.Contents
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Gliomas are the most common primary brain tumors in adults,
which results from astrocytes or glial precursors transformation.
Glioblastoma or glioblastoma multiform (GBM) is the most
frequent, aggressive and high-grade (grade IV) form of glioma that
occurs in brain or spinal cord. Despite all remarkable progressions
in neurosurgery, drug (gene and cell therapy, boron neutron cap-
ture therapy, nanotechnology-based therapies) and radiation,
various cancer such treatment is still an important concern and the
chance of treatment is not promising [1e5]. The usual span of
survival following diagnosis is almost fewer than 5 years [6,7]. The
cellular and molecular origin of GBM is not yet fully understood.
But, it was shown that dysregulation of cellular signaling pathways
and genetic mutations can play a critical role in cancer ignition,
invasion and progression. For instance, the hyperactivation of PI3
kinase pathway, mutation in retinoblastoma and p53 genes, and
overexpression of epidermal growth factor receptor (EGFR) were
reported in GBM cases [8e10].
From past decades, herbal and natural compounds or their de-
rivatives have attracted much attention as promising therapeutic
agents to treat human malignancies, especially cancers. Curcumin
is an herbal supplement originating from turmeric (root of the
rhizome Curcuma longa) and belongs to curcuminoids group, which
are plant phenols metabolites causing yellow color in turmeric
[11,12]. Chemically, curcumin is a natural linear diarylheptanoid
consisting of two aromatic rings which bind to a heptane with
various substitutions. Schematic 1 shows themolecular structure of
curcumin [13]. Without any doubt, curcumin plays pivotal roles in
various biological processes by its pharmaceutical benefits to
remedy diseases. Strong evidences have approved that this poly-
phenol compound possesses immense biological activities,
including anti-oxidant, anti-inflammatory [14], cardioprotective
[15], neuroprotective [16], as well as anti-cancer [17]. It is worth
notice that lipophilic properties of curcumin and its ability to cross
into blood brain barrier (BBB) make it an efficient therapeutic and
protective agents in CNS-related disorders and malignancies,
including Alzheimer’s [18], Parkinson [19] and GBM [20].
Despite the significant beneficial effects of curcumin, the low
bioavailability impedes its wide utilization in medicinal and phar-
maceutical applications. To overcome this drawback, many efforts
have been focused on developing novel curcumin derivatives, such
as demethoxycurcumin (DMC), tetrahydrocurcumin (THC), tur-
merones and bisdemethoxycurcumin. In comparison to curcumin,
altering some substitutions causes an improvement in their
bioavailability and biological activities.
Emerging nanotechnological strategies have caused a significant
progress inmany sciences, including biology andmedicine. In order
to improve the bioavailability and efficacy of curcumin and its an-
alogues, nanomaterials are used as carriers for their drug delivery.
Up to now, many researchers have been interested in curcumin, its
analogues and also their related delivery systems to treat many
cancers, particularly GBM.
The purpose of this review is to summarize current researches
on curcumin in GBM therapy. The curcumin roles and molecular
mechanisms involved in GBM treatment have been wellintroduced. Then, the investigations related to curcumin analogues
and curcumin delivery systems for GBM cells have been addressed.2. Curcumin as a therapeutic agent in glioblastoma
From the past centuries, products derived from nature have
been used for wound healing and disease treatment. Recently, the
health application and benefits of these natural compounds have
become an attractive research field in modern medicine [21]. Many
natural-based components have been identified potentially used in
medical applications and disease treatment. Due to intrinsic
properties, some of them can penetrate BBB, which is one of the
principal consideration for developing drugs for central nervous
system (CNS) [22,23].
Curcumin is an example of natural pharmaceutical compounds
which is able to permeate BBB and mainly accumulates in hippo-
campus. As for abundant amounts of lipids in brain, the lipophilic
nature of curcumin causes favorable absorption, availability as well
as maintenance in CNS [24]. Numerous studies have investigated
the wide range of curcumin pharmaceutical effects, such as anti-
microbial, anti-inflammatory, anti-oxidant and especially anti-
cancer [25e27]. Regarding this, curcumin has been reported as an
effective anti-tumor agent against GBM (Fig. 1), the most lethal
primary CNS tumor [28,29].
Many evidences have shown the curcumin ability to arrest cell
proliferation and induce apoptosis in various cancers, such as colon
cancer [30], lung cancer [31], breast cancer [32], melanoma [33], as
well as GBM [34]. The apoptotic function of curcumin is related to
induce ROS production, caspases activation and mitochondrial
membrane permeability and so on [35,36]. Ambegaokar and col-
leagues reported that curcumin could inhibit proliferation and
induce apoptosis of GBM cell line. The mechanisms would be either
p53 and caspase 3 activation or decreasing anti-apoptotic genes,
including AP-1, NF- kB and Bcl2 [37]. Curcumin attenuates cell
proliferation and overcomes radioresistant and chemoresistant
GBM cells. The molecular mechanisms of this action are related to
AP-1 and NF-kB pathways through inhibition of JNK and AKT acti-
vation. The decreased expression of bcl-2, and DNA repair enzymes,
such as MGMT, ERCC-1, DNA-PK, Ku70 and Ku80 lead to the resis-
tance of glioma cells against radiation and chemotherapeutic
agents; however, these cells are sensitive to curcumin. Subse-
quently, this feature proposes that curcumin is potentially useful as
an adjutant with common chemotherapeutic agents and radiation
in GBM treatment [27].
It has been reported that curcumin inhibits migration and in-
vasion in GBM cell line U87. A 6 h exposure of 10 mM curcumin
causes a significant decrease in Fascin protein expression by
inhibiting STAT3 pathway. A reduction in Fasin expression results in
cell shape alternation and filopodia formation reduction in
U87 cells [38]. Fascin is an acting binding protein involved in F actin
aggregation, cellular cytoskeleton rearrangement and cell motility.
The Fascin expression is associatedwith invasive behavior of cancer
cells, including GBM cells [39]. Of note, the ability of cells for
attachment, invasion and migration shows a negative correlation
with curcumin concentration and exposure time [40]. Molecular
mechanisms and related signaling pathways of anti-tumor
Fig. 1. Curcumin and its therapeutic effects on glioblastoma.
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purpose, three core pathways investigated in GBM include: 1) the
p53 pathway (p53, p21 and cdc2 proteins), 2) PI3kinase pathway
(EGFR, Ras, mTOR, PTEN and Akt), and 3) RB pathway (CDKN2A/16
and RB proteins). In a time and dose dependent manner, curcumin
either promotes p53 signaling through increasing p53 and p21 and
decreasing cdc2 proteins or reduces RB pathway by increasing and
decreasing CDKN2A/p16 and phosphorylated RB, respectively. But,
it has no significant effect on expression of PI3Kinase of mentioned
proteins. Also, it has been shown that increased concentration of
curcumin may induce morphological changes in cells, from a flat
and columnar shape to small and shrink cells. Furthermore, the
cells population arrested in G2/M phase are increased significantly
with elevating curcumin concentration and exposure time in
DBTRG cell line [41]. Regardless PTEN and p53 mutational status,
curcumin inhibits survival pathways, PI3kinase and NF-kB, and bcl-
xl, an anti-apoptotic protein. Moreover, curcumin exerts a synergic
effects with cis-platin and doxorubicin to reduce GBM tumor size
in vivo [42].
Perry and colleagues reported anti-carcinogenesis features of
curcumin in GBM xenografts. Curcumin administration decreases
metalloproteinase-9, gelatinolytic activities, and endothelial cell
markers which is an indication of decreased angiogenesis [20].
Furthermore, the restrained effects of curcumin on proliferation,
colony formation, migration and tumor size have been evaluated in
glioma cell lines and mice model. Curcumin treatment leads to
downregulation of SHH/GLI1 signaling (GLI1, Smo and Shh),
CyclinD1, Bcl-2 and Foxm1 in vitro. It also increases the Bax/Bcl2
ratio, leading to induce apoptosis in tumor cells. Curcumin restrains
tumor cells and prolongs the survival period of U87-implanted
nude mice compared to control subhects through SHH/GL1
signaling pathway [43].
MicroRNAs (miRNAs) are a class of small non-coding RNAs
which play critical roles in post-transcriptional gene regulation.
Due to miRNA roles in the regulation of cellular processes and
pathways, their aberrant expression can lead to seriousmalignancies, including cancers [44,45]. Evaluating the expres-
sion of miR-378 revealed that this miRNA is significantly
expressed in lower levels in brain tumor tissues. Eventually, miR-
378 acts as a tumor suppressor miRNA and inhibits malignant
characteristics of glioma [46]. Furthermore, miR-378 enhances the
anti-tumor effects of curcumin, and GBM cells response to cur-
cumin treatment through mediating p38 mitogen-activated pro-
tein kinase [47]. MiRNA-21 is a well-known oncogene miRNA
which is a key regulator in GBM progression [48]. Curcumin re-
duces pri-miR-21 promoter activity via binding to AP1, a tran-
scription factor activating its promoter [49]. Also, curcumin
decreases the carcinogenicity of GBM cells through inhibition of
miR-21 and anti-apoptotic proteins, and enhances the expression
of pro-apoptosis proteins as well as microtubule-associated pro-
tein light chain 3-II (LC3-II) expression [50].
Cancer stem cells (CSCs), a small population in tumor environ-
ment, are responsible for tumor developing, progression, recur-
rence and drug resistance in cancers, including GBM [51]. Mounting
evidences suggest that curcumin is able to target glioma CSCs
through molecular pathways involved in self-renewal. Exposure of
glial CSCs to curcumin results in differentiation and self-renewal
dysfunction. In glial CSCs, the neurospheres forming ability and
neural stem/progenitor markers (CD133 and Nestin) expression are
also repressed by treatment of curcumin, even at low concentration
(2 mM) [52]. Meanwhile, curcumin (2.5 mM) makes a remarkable
arrest in GBM stem cells via MAPK pathway activation, STAT3 and
IAP inhibition, and in a ROS-dependent approach. Thus, curcumin
potentially prevents GBM recurrence through anti-proliferative
effects on stem cells [53]. Table 1 illustrated the anti-tumor ef-
fects of curcumin in GBM (see Table 2).2.1. Curcumin analogues
Without doubt, curcumin has beneficial effects on inhibition of
tumor cell growth. Despite remarkable anticancer features of cur-
cumin, its application in experimental and clinical practices has
Table 1
Anti-tumor effects of curcumin on glioblastoma.
Dose (s) Main target (s) Main effect (s) Model Cell line (s) Ref
10 mM Atg5, Beclin-1 Induces autophagy In vitro A172 [54]
10 mM Fascin Anti-migration and anti-invasion effects In vitro U87 [40]
10 mM Cx43 Induces apoptosis In vitro U251, U87 [55]
25 mM Atg5, Atg7,m PI3K, Akt/mTOR Pathway Induces autophagy In vitro U-87MG, GL261, F98,
C6-glioma N2a
[56]
50 mM IRE1, ATF6, miR-27a, 222, 449, AKT-
Insulin and p53-Bcl-2 pathways
Induces apoptosis In vitro A172 [57]
20 mM CDK1, cyclin A/B, PI3K/AKT, COX-2, NF-kB, Anti-proliferative and anti-migration effects, induces
apoptosis
In vitro U118MG, U87MG,
U251MG SVG, p12
[58]
0.05, 0.1, 0.25, 1, 2.5,
5, 7, 8, 10 mM
e Increases survival
Inhibits tumor growth, induces apoptosis
In vitro C6 [59]
25 & 2.5 mM STAT3, Survivin, MAPK, IAP1, IAP2 Anti-proliferative effects, induction of ROS in tumor cells In vitro Glio 3, 4, 9, 11, 14 [53]
10, 20 and 40 mM miR-326 Cytotoxic effects against tumor cells, induces apoptosis, Anti-
proliferation and anti-migration effects
In vitro U87, U251 [60]
22.5 mM Arginase, iNOS, NF-kB, STAT1 Repolarized tumor-associated microglial cells to the
tumoricidal M1 state, increases survival
In vitro,
In vivo
GBM994, GBM46,
GBM6, GL261, CD68
[61]
46.4 mM,
78,3 mM, and 47.7 mM
MMPs, glucose-6-phosphate transporter Induction of cell death In vitro GB3B, GB4B, GB5B [62]
20 and 40 mM cyclin G2, caspase-3, FasL,
CDK1, FoxO1
Induces cell cycle arrest and apoptosis, anti-proliferative
effects
In vitro U87 [63]
20 & 100 mM miR-146a, NF-kB Anti-proliferative effects, induces apoptosis In vitro U-87 [64]
50 mg/kg STAT3, NFkB, PI3K/Akt Induces autophagy and apoptosis In vitro,
in vivo
U251MG, U87M [65]
1.25 mg/ml AKT, mTOR Exerts synergistic effects with chemotherapy drug, induces
apoptosis
In vitro,
In vivo
U87MG [66]
8,15, 25, 667 mM NF-kB, cyclin D1, VEGF Reduces tumor load and increases survival of glioblastoma-
implanted mice
In vitro T98G, U87MG, GL261 [67]
30, 40 mM STAT3 Induces RANK gene reactivation by epigenetic modification In vitro U251
U87
[68]
2 mM GFAP, bIII-tubulin, LC3 Induces autophagy In vivo,
In vitro
SU-2, SU-3 [69]
50 mg/kg/day PI3K/Akt, NF-kB
Caspase-3
Inhibits proliferation and migration, induces cell death In vivo,
In vitro
U138MG, U87
U373
C6
[70]
10, 20, and 50 mM STAT3 Anti-proliferative, anti-migratory, and anti-invasive effects In vitro A-172 MZ-18, MZ-54
MZ-256, MZ-304
[71]
10, 20 and 30 mg/ml. EGFR, mTOR, Ras, PTEN, RTK-Ras-PI3K,
Bax, caspase-3
induces cell cycle arrest
Induces apoptosis
In vitro DBTRG [72]
30, 60, 120 mg/kg/day MMP-9 Anti-angiogenesis effects In vivo,
In vitro
U-87 [73]
5, 10, or 20 mM/L Waf1/Cip1, ERK, JNK, MAPK/Elk-1/Egr-1
pathway
Exerts anti-proliferative effects, induces cell cycle arrest,
Regulates differentiation, growth, and apoptosis
In vitro U-87MG C6 [74]
25e50 mM/L p53- and caspase-, AP-1 and NFkappaB, JNK
and Akt, bcl-2 and IAP
Suppresses cell growth and chemotherapy resistance In vitro T98G, U87MG, T67, C6 [75]
25 and 50 mM caspase-3, -8, -9
Bax, Bcl-2,
NF-kB, SBDP
Induces apoptosis In vitro U87MG [76]
25 and 50 microM caspase-3, -8, -9
Bax, Bcl-2,
NF-kB, SBDP
Induces apoptosis In vitro T98G [77]
Table 2
Various curcumin analogues in glioblastoma therapy.
Type of
curcumin
Dose (s) Target (s) Effect (s) Model Type of cell
line (s)
Ref
(1) 2.7e5.8 mM CHOP, p-jun, caspase-12 Promotes Endoplasmic Reticulum Stress and
apoptosis
In vitro GSCs [102]
(2) 100 mM Ca2þ/calmodulin-dependent protein kinase II,
CD133, Sox2
Anti-migration and anti-invasion effects, induces
apoptosis
In vitro U87MG,
U373MG
[103]
(3) 100 mM TAC Antioxidant effects In vitro C6 [104]
(4) 10, 30, and
50 mg/kg
JAK, STAT Inhibits proliferation and induces apoptosis In vitro,
In vivo
GSCs [93]
(4) 10 & 30 mM ROS, caspase-3-JAK/STAT3 Induces apoptosis, anti-proliferation effects In vitro,
in vivo
U87, U251 [105]
(4) ROS, caspase-3, JAK/STAT3 Anti-proliferative effects, inhibits of cell growth,
induces apoptosis
In vitro GSCs [106]
(5) 12.5e100 mM Caspase-3, -8, -9, NF-kB Anti-proliferative effects, induces apoptosis In vitro GBM 8401 [107]
Bis-chalcone 4j (1); Hydrazinobenzoyl curcumin (2); Curumin-[G-2]-OH (3); Demethoxycurcumin (4); 1,7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3,5-dione (5).
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water. These drawbacks have pushed researchers to develop cur-
cumin derivatives which are as effective as curcumin even at
micromolar dosage [78].
There are three sectors in the curcumin structure which have
been modified in order to produce an “improved curcumin.” These
contain the aromatic rings, the -diketone moiety, and the two
flanking double bonds conjugated to the latter. Synthesis of ana-
logues can improve anticancer potential to target different pro-
cesses or stages in cancer cells. Structure activity relationship (SAR)
analysis suggests that a variety of structural types are tolerated for
potency [79].
The curcuminoids such as curcumin, demethoxy curcumin and
bisdemethoxycurcumin were isolated from the dichloromethane
extraction by chromatography. The pyrazole analogues could be
prepared by treating the CH2Cl2 extract with hydrazine hydrate in
acetic acid and purificatio by chromatography to give pyrazole
derivatives [80]. The isoxazole analogues were prepared by treating
the CH2Cl2 extract with hydroxylamine hydrochloride in acetic
acid and purification by chromatography. All the compounds
demonstrated antioxidant effect; while, among them the pyrazole
analogue was showed to be more potent than curcumin but the
potential of isoxazole analogue was equipotent to curcumin [81].
2.2. Curcumin analogues as powerful tools in glioblastoma therapy
To date, the curcumin analogues have attracted many attentions
to be used as anti-cancer agents against a plethora of cancers,
including GBM (Fig. 2). The DMC, THC, turmerones and bisdeme-
thoxycurcumin are considered as curcumin analogues inducing
inflammatory and anti-proliferative signals via inducing reactive
oxygen species (ROS), and potentially can be used as chemo-
protective components for cancer treatment [82]. It was investi-
gated that DMC concentration 50 mg/ml could induce ROS
production, majorly superoxide anion radical (O2$), and followingFig. 2. Curcumin analogues. Bis-chalcone 4j (1); Hydrazinobenzoyl curcumin (2); Curum
heptadiene-3,5-dione (5).apoptosis in U87 cells. Based on bioinformatics analysis, DMC could
interact with active site residues of mitochondrial superoxide dis-
mutase (mnSOD) and inhibit its activity, resulting in O2$ accumu-
lation in cells. In that study, exposure to DMC lead to suppression of
PI3kinase/NF-kB signaling and activation of caspase-8 and caspase-
9 to release cytochrome c, resulting in cell growth arrest and
apoptosis in human glioma U87 MG cells [83]. Furthermore, it was
revealed that DMC treatment induces G2/M cell arrest and
apoptosis through activation of Bcl-2 in those cells [84]. In addition
to induction of ROS generation, DMC not only decreased the
expression of CDC25C, Cyclin B1 and CDK1 leading to G2/M cell
arrest, but also increased ubiquitination and proteasome degrada-
tion in U87 cells [85]. Additionally, DMC showed cytotoxic activities
against GBM 4801 cells, a humanmalignant GBM cell line. DMC has
been observed to reduce the mitochondrial membrane potential
(MMP), and to increase DNA fragmentation and apoptosis via
activation of caspase-3 and caspase-9 in GBM cell lines. It also in-
hibits NF-kB signaling pathway, and contributes to arrest cells in
SubG0/G1 cell phase [86]. ATP-binding cassette sub-family G
member 2 (ABCG2) is a drug transporter overexpressed in glioma
stem cells (GSCs), and increases chemotherapy resistance in them
[87]. ABCG2 expression showed an inverse correlation with DMC-
induced growth inhibition in GSCs, and its suppression resulted
in an improvement in DMC efficacy, ROS production and apoptosis
induction. This datawas also confirmed in xenograft tumor-bearing
mice; the ABCG2 expression was reversely related to anti-tumor
effects of DMC on GSCs. These findings suggested ABCG2 expres-
sion as a critical mechanism of resistance to DMC and a potential
therapeutic target for GBM treatment [88].
Temozolomide (TMZ) is one of the widely used chemothera-
peutic agents for GBM treatment, which induces cell apoptosis, cell
growth inhibition and autophagy in GBM cells through O6-meth-
ylguanin formation. Despite impressive antiglioma impacts of TMZ,
it cannot effectively inhibit cancer recurrence and CSCs prolifera-
tion [89e91]. It was proposed that DMCmay be better than TMZ forin-[G-2]-OH (3); Demethoxycurcumin (4); 1,7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-
Z. Shabaninejad et al. / European Journal of Medicinal Chemistry 188 (2020) 1120406GSCs therapy, because it could effectively prohibit cell proliferation
and activate apoptosis in vitro and in vivo. The GSCs were negligibly
affected by a single dosage of TMZ, however, its combination with
DMC synergically increased GSCs apoptosis through modulating
ROS generation, caspase-3 signaling activation, and suppression of
JAK/STAT3 and PCNA expression [92,93]. Consistently, Shi et al.
showed that DMC more effectively induces cell proliferation arrest
and apoptosis activation than TMZ treatment in GBM cell lines and
animal model. Similarly, the co-administration of TMZ and DMC
synergically results in anti-tumorigenic effects through the same
mechanisms presented for GSCs treatment in vivo and in vitro [94].
Recently, this research group has published contradictory results
which refused their previous conclusions. They demonstrated that
TMZ is significantly able to induce tumor regression compared to
DMC in xenograft GBM mice model. In addition, TMZ has more
effective inhibitory effects on expression of Ki67 and proliferating
cell nuclear antigen (PCNA). Moreover, only TMZ but not DMC in-
duces a p-AKT decrease and an increase in cleaved caspase-3 and
BAX expression [95]. These findings caused a dilemma about DMC
and TMZ efficacies in glioblastoma treatment, and it seems that
more reliable and accurate researches are needed to clear this
ambiguity.
Zhang and colleagues have recently revealed that THC synergi-
cally increases radiosensitivity of glioma cells. Therefore, compared
to single treatment, a combination therapy of THC and radiation
exposure increases apoptosis and G0/G1 cell growth suppression.
Also, the S phase cell population and cyclin D1 and PCDNA
expression were significantly decreased. Tumor growth was
remarkably inhibited in animals treated with combination therapy
[96]. Hydrazinobenzoylcurcumin (HBC) is a recently developed
derivative of curcumin acting as a Caþ2/Calmodulin antagonist to
inhibit tumor growth in various cancer cells [97,98]. HBC has a
significant role in the suppression of tumorigenic features of GSCs.
It not only reduces the self-renewal capacity, migration and inva-
sion, but also promotes caspase-3 and caspase-9 as well as
apoptosis process in GSCs. It is worth pointing out that the
expression of CD133, Nanog, Sox2 and Oct4, a GSC marker, is
considerably decreased due to HBC-induced repression of Caþ2/
Calmodulin-dependent protein kinase II (CaMKII) and c-Met ac-
tivity [99]. CaMKII modulates many signaling cascades, such as c-
Met signaling which is responsible for expression of stemness
markers, through activation of ERK1/2, PI3kinase and STAT3 pro-
teins [100,101]. It was suggested that CaMKII might be a novel
therapeutic target to induced apoptosis in GSCs [99]. Table 3 listed
various curcumin analogues in GBM therapy.
3. Novel therapeutic approaches for curcumin targeting in
glioblastoma
Many researches have been clearly approved the chemo-
protective and chemotherapeutic effects of curcumin on a wide
range of cancers. Although curcumin retards tumor growth, the
poor oral bioavailability limits its wide clinical application. It is
mainly because of low absorption, rapid metabolisms, as well as
rapid elimination from the body [33,108]. Nanomaterial-mediated
targeting system is a promising approach to overcome these
problems and raise the possibility of being widely used as a com-
mon anticancer therapy [109]. Therefore, developing delivery sys-
tems for curcumin has attracted many attentions in recent years. In
the following part, recent researches about nanodelivery of cur-
cumin to GBM cells are discussed (Table 3).
3.1. Nanoformulation of curcumin
Different types of nanomaterials, such as polymer nanoparticles,polymeric micelles, and liposomes have been used as nanocarriers
to deliver curcumin. Bisht et al. developed a polymeric nanoparticle
formulation of curcumin (NanoCurc™) that overcomes the major
drawback of free curcumin, low bioavailability, and improves
treatment efficacy. NanoCurc™ is 50 nm in size synthetized by
encapsulation of curcumin in cross-linked and random copolymers
of N-isopropylacrylamide (NIPAAM), N-vinyl-2-pyrrolidone (VP),
and poly (ethyleneglycol) monoacrylate (PEG-A). Compared to free
curcumin, it showed more solubility in aqueous medium. In addi-
tion, its anti-tumorigenic effects on various human cancer cell lines
and animal models of human malignancies were remarkable and
extremely promising [110,111]. Also, NanoCurc™ showed inhibitory
effects on cell proliferation and clonogenecity, and stem-like
behavior was examined in GBM and medulloblastoma, as malig-
nant brain tumors. The results showed that this formulation dose-
dependently induces a decrease in growth by arresting cells in G2/
M cell cycle phase and an apoptotic induction in various tumor-
derived cells, including DAOY, D283Med, GBM neurosphere lines
HSR-GBM11 and JHH-GBM14. Furthermore, this polymeric encap-
sulation of curcumin attenuates clonogenic growth and CD-133-
positive stem-like cell population. Downregulation of some
immense cellular pathways, including insulin like growth factor,
STAT3 as well as Hedgehog signaling pathways can be considered
as possible mechanisms for the cellular changes in mentioned cells.
Overall, this curcumin nanoparticle is able to inhibit the progres-
sion of malignant brain tumors through regulation of cell prolifer-
ation, survival and stem cell phenotype [112]. Methoxy
polyethylene glycole-poly caprolactone (mPEG-PCL) is an amphi-
philic copolymer widely used in medical means and drug delivery
systems. Curcumin is loaded in this copolymer to form a core-shell
structure. The prepared nanocurcumin is permeated to cells with a
significant efficiency through endocytosis mechanism and is
localized near the nucleus. In a dose-dependent manner, this
nanocurcumin could stimulate pro-apoptosis mechanism in rat
model of GBM [113]. Furthermore, curcumin loaded in mPEG-PCL
and PCL showed high neuroprotective effects on U251 glioblas-
toma cells. Treatment of U251 cells and zebrafish embryos with
these two nanocurcumins revealed desirable cellular uptake [114].
3.1.1. Solid lipid curcumin particles
Recently, it was shown that solid lipid curcumin particles (SLCP)
more efficiently induce apoptosis and anti-tumorigenesis effects
than free curcumin on GBM. Besides, the SLCP causes an
enhancement in autophagymarkers (Atg5, Atg7, Beclin-1, LC3A/BeI
and LC3A/B-II) and cell survival markers. Inversely, PI3kinase
pathway (PI3kp85, p-PI3kp85, total AKT, p-AKT, mTOR and P-
mTOR) and cell death markers are increased after treatment of cells
with SLCP. Subsequently, the authors demonstrated that SCLP could
be a non-dangerous and effective carrier for therapeutic application
by autophagy regulation in GBM cells [115].
3.1.2. Cucrumin-loaded lipid-core nanocapsules
Cucrumin-loaded lipid-core nanocapsules (C-LNCs) has been
developed to overcome low bioavailability of curcumin and
improve anti-tumor properties of curcumin. Release of curcumin
from lipid nanocarrier was efficiently controlled in C6 and U251MG
cells. Furthermore, C-LNC shows more cytotoxic effects compared
to non-capsulated curcumin in vitro. Arresting in G2/M cell cycle
phase and autophagy induction were reported in cells treated with
C-LNC and free-curcumin. As well, an in vivo investigation indicated
a significant decrease in brain tumor size and a prolonged survival
compared to animals injected with same dose of non-capsulated
curcumin [116]. Phytosome, a complex of a natural (usually herb-
al) compound and a phospholipid, is appropriate to be used as drug
delivery system [117]. Curcumin Phytosome Meriva (Meriva®) has
Table 3
Curcumin delivery systems in glioblastoma therapy.
Novel curcumin formulation Dose (s) Target gene (s) Effect (s) Model Type of cell
line (s)
Ref
Nano micelles curcumin 80 mg cyclin D1, Wnt, NF-kB Inhibits tumor cell growth, induces apoptosis, anti-
invasion effects
In vitro U-373 [128]
Micellar curcuminoids 70 mg Intratumoral inorganic
phosphate (Pi)
Anti-cancer effects Human e [129]
Curcumin loaded PLGA
nanoparticles
10 mM Tyrosine phosphorylation Anti-cancer effects In vitro DKMG [130]
Solid Lipid Curcumin Particles 25 mM Caspase-3, Bax, p53, Bcl2, c-Myc,
Akt
Induces apoptosis In vitro U-87MG
GL261
[131]
Curcumin-loaded polymeric micelle miR-21, PDCD4, PTEN Induces apoptosis, reduces the tumor size In vitro C6 [132]
Dendrosomal curcumin GADD45, NF-kB and c-Myc Induces apoptosis In vitro U87-MG [133]
Nanoformulation of curcumin and
doxorubicin
Caspase-3, -7
GLUT1
Induces apoptosis In vitro U87MG [134]
Micellar curcuminoids 70 mg Intratumoral inorganic
phosphate (Pi)
Anti-tumor effects Human [134]
Lipid droplets of curcumin 5e100 mM Caspase-3 Induces apoptosis In vitro U251N [135]
Curcumin loaded R7L10 micelles pDNA Induces apoptosis, reduces the tumor size In vitro,
In vivo
C6 [136]
Curcumin-loaded nanocarrier 24.23 mM e Anti-cancer effects In vitro,
In vivo
U87 [137]
Dendrosomal curcumin 15, 17.5,
20 mM
OCT4A, OCT4B1, SOX-2, miR-145 Inhibits cancer cell growth, Exerts anti-proliferative
effects
In vitro U87MG [138]
Phytosomal curcumin 2 mg STAT1, STAT3, ARG1, IL-10, iNO,
caspase-3
Anti-cancer effects In vivo GL261 [139]
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absorption and higher bioavailability than free curcumin [118]. It
was reported that GBM -antibody-linked curcumin (CC) and Mer-
iva® could complete remission in approximately 60% of GBM mice
models. One possible mechanism can be repolarizing tumor-
associated microglia/macrophages (TAM) from the tumor-
promoting M2 type to tumoricidal M1-type [119e121]. Also, Mer-
iva® treatment induces 50%e60% of the TAM and activates natural
killer cells (NK) to GBMmicroenvironment. Downregulation of M2-
linked tumor-promoting proteins (STAT3, ARG1 and IL10), induc-
tion of M1-linked anti-tumor proteins (STAT1 and nitric oxide
synthase) in the TAM, clearance of CD133 (þ) GBM stem cells and
activation of apoptosis through caspase-3 in tumor cells were
introduced as potential mechanisms in Meriva®-mediated treat-
ment of mice bearing GBM GL261 cells.3.1.3. Polysaccharide nanoparticles
Two opposite polysaccharides mixing in aqueous solution cau-
ses electrostatic interactions and subsequently, polysaccharide
nanoparticles (PSNPs) are spontaneously formed [122]. Chitosan
(CS) is an amino polysaccharide with linear structure. It is found in
nature, and promising future for its utilization in clinical practice
can be considered. The positive charge at natural and acidic pH
provides PSNPs preparation [123]. Hyaluronic acid (HA) also called
hyaluronan, is a negatively charged and non-sulfated glycosami-
noglycan having ability to bind CD44 receptor overexpressed in a
plethora of cancers [124]. Lactoferin (Lf) is a positively charged and
iron-binding glycoprotein in mammalians. BBB and glioma cells
express its receptor on their surfaces and facilitate Lf transportation
[125]. In a study conducted by Xu et al., in order to provide non-
invasive and efficient treatment for GBM, HA and CS hydrochlo-
ride (as negatively and positively charged polysaccharides,
respectively) were used to form PSNPs as a carrier for curcumin. In
addition to PSNPs, further functionalization with Lf caused a dual
targeting drug delivery of curcumin to cross BBB and target glioma
cells. In vivo and in vitro studies have reported that Lf-curcumin-
PSNPs could cross the BBB efficiently. The results show that Lf-
curcumin-PSNPs could target and accumulate in brain tumor after
increased BBB crossing, hence it has a vast potential to be used inCNS-related malignancies therapy [126]. Another study carried out
by Yang et al., revealed the potential of PSNP-based HA/CS poly-
saccharides to delivery curcumin against GBM cells. Compared to
non-capsulated curcumin, curcumin-PSNP significantly induces
cytotoxicity and higher uptake in C6 cell line. Active endocytosis,
micropinocytosis, clathrin-, CD44and caveolae-mediated endo-
cytosis may be involved in curcumin-PSNP uptake in C6 cells [127].
Overall, further investigations are required to prove the effec-
tiveness of mentioned nano-based delivery systems of curcumin in
the therapy of GBM.
4. Conclusion
As mentioned earlier, GBM implicates multimodality clinical
therapies, such as radiotherapy, chemotherapy and surgery. Ma-
lignant gliomas often show radio- and chemo-resistance. Due to
the diffuse and aggressive nature of this cancer, and because of poor
outcomes of standard therapies, efficient therapeutic methods for
GBM treatment are still required. Curcumin has shown beneficial
anticancer effects in various malignancies, including GBM. The
synergistic impacts of curcumin with radiotherapy and chemo-
therapy revealed its potential for GBM therapy. Application of this
natural compound in combination therapy for affected individuals
has a promising future.
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5. List of abbreviations
GBM Glioblastoma or glioblastoma multiform
DMC Demethoxycurcumin
THC Tetrahydrocurcumin
CNS Central nervous system
BBB Blood brain barrier
miRNAs MicroRNAs
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mnSOD Mitochondrial superoxide dismutase
MMP Mitochondrial membrane potential
ABCG2 ATP-binding cassette sub-family G member 2
GSCs Glioma stem cells
TMZ Temozolomide
PCNA Proliferating cell nuclear antigen
HBC Hydrazinobenzoylcurcumin
CaMKII Caþ2/Calmodulin-dependent protein kinase II
NIPAAM N-isopropylacrylamide
VP N-vinyl-2-pyrrolidone
PEG-A Poly (ethyleneglycol) monoacrylate
mPEG-PCL Methoxy polyethylene glycole-poly caprolactone
SLCP Solid lipid curcumin particles
C-LNCs Cucrumin-loaded lipid-core nanocapsules
TAM Tumor-associated microglia/macrophages
PSNPs Polysaccharide nanoparticles
CS Chitosan
HA Hyaluronic acid
Lf Lactoferin
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